Nutraplus India Ltd
Nutraplus India is engaged in the Business of Drugs and Pharmaceuticals.
- Market Cap ₹ 7.16 Cr.
- Current Price ₹ 2.10
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 19.2
- Dividend Yield 0.00 %
- ROCE 2.89 %
- ROE -2.73 %
- Face Value ₹ 5.00
Pros
- Stock is trading at 0.11 times its book value
Cons
- Company has low interest coverage ratio.
- Contingent liabilities of Rs.3.89 Cr.
- Working capital days have increased from 29.6 days to 60.5 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2014 | Mar 2015 | TTM | |
|---|---|---|---|---|
| 45 | 62 | 65 | 63 | |
| 38 | 51 | 62 | 59 | |
| Operating Profit | 6 | 10 | 3 | 3 |
| OPM % | 14% | 17% | 5% | 5% |
| 0 | 0 | -3 | -23 | |
| Interest | 2 | 4 | 5 | 4 |
| Depreciation | 1 | 2 | 1 | 1 |
| Profit before tax | 4 | 5 | -6 | -25 |
| Tax % | 31% | 39% | -28% | |
| 3 | 3 | -4 | -24 | |
| EPS in Rs | 2.59 | 2.41 | -1.66 | -20.13 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| TTM: | -8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -111% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -31% |
| 5 Years: | -6% |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2014 | Mar 2015 | |
|---|---|---|---|
| Equity Capital | 5 | 6 | 11 |
| Reserves | 8 | 14 | 36 |
| 15 | 32 | 40 | |
| 16 | 23 | 27 | |
| Total Liabilities | 44 | 75 | 114 |
| 19 | 36 | 23 | |
| CWIP | 0 | 1 | 13 |
| Investments | 2 | 0 | 4 |
| 23 | 39 | 74 | |
| Total Assets | 44 | 75 | 114 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2014 | Mar 2015 | |
|---|---|---|---|
| 4 | -16 | ||
| -11 | -5 | ||
| 7 | 32 | ||
| Net Cash Flow | 0 | 10 | |
| Free Cash Flow | -7 | -37 | |
| CFO/OP | 26% | -513% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2012 | Mar 2014 | Mar 2015 | |
|---|---|---|---|
| Debtor Days | 98 | 88 | 75 |
| Inventory Days | 82 | 170 | 134 |
| Days Payable | 151 | 168 | 187 |
| Cash Conversion Cycle | 30 | 89 | 22 |
| Working Capital Days | 57 | -1 | 61 |
| ROCE % | 3% |
Insights
In beta| Sep 2016 | Mar 2020 | Jun 2025 | |
|---|---|---|---|
| Number of Manufacturing Units Number ・Standalone data |
|
||
Documents
Annual reports
Concalls
-
Sep 2016TranscriptAI SummaryPPT